Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers

Antonis C Antoniou1*, Karoline B Kuchenbaecker1, Penny Soucy2, Jonathan Beesley3, Xiaoping Chen2, Lesley McGuffog1, Andrew Lee1, Daniel Barrowdale1, Sue Healey4, Olga M Sinilnikova4, Maria A Caligo5, Niklas Loman6, Katja Harbst6, Annila Lindblom7, Brita Arver8, Richard Rosenquist9, Per Karlsson10, Kate Nathanson11, Susan Domchek11, Tim Rebbeck11, Anna Jakubowska12, Jan Lubinski12, Katarzyna Jaworska12, Katarzyna Durda13, Elżbieta Złowowcowa-Perfilowska12, Ana Osorio14, Mercedes Durán15, Raquel André16, Javier Benítez17, Ute Hamann18, Frans B Hogervorst19, Theo A van Os20, Senno Verhoeven21, Hannele Meijers-Heijeboer22, Juul Wijnen23, Encarna B Gómez Garcia24, Marjolin J Lijtenberg25, Mieke Krieger26, J Margriet Collée27, Margreet GEM Ausems28, Jan C Oosterwijk29, Susan Peock1, Debra Frost1, Steve D Ellis1, Radka Platte1, Elena Fineberg1, D Gareth Evans31, Fiona Lalloo31, Chris Jacobs32, Ros Eeles33, Julian Adlard34, Rosémie Davidson35, Trevor Cole36, Jackie Cook37, Jan Poters38, Fiona Douglas39, Carole Brewer40, Shirley Hodgson41, Patrick J Morrison42, Susan Domchek43, Debra Frost44, Steve D Ellis45, Andrew K Godwin46, Andrew T Kwek47, Dominique Stoppa-Lyonnet48, Claude Houdayer49, Bruno Bueche50, Antoine de Paauw51, Sylvie Mazoyer52, Alain Calender53, Matthieu Gelin54, Brigitte Bressac-de Pailleters55, Olivier Caron56, Hagay Sobol57, Marc Frenay58, Fabienne Prieur59, Sandra Fert Ferrel60, Isabelle Mortemousque61, Saundra Buys62, Mary Daly63, Alexander Miron64, Mary Beth Tenney65, John L Hopper66, Esther M John67, Melissa Southey68, David Goldgar69, Christian F Singer70, Annelies Fink-Retter71, Muy-Kheng Tea71, Daphne Geschwantler Kaulich71, Thomas VO Hansen72, Finn C Nielsen72, Rosa B Bairdottir73, Mia Gaudet74, Tomas Kirchhoff75, Vjia Joseph76, Ana Dutra-Clarke77, Kenneth Offit77, Marion Piedmonte77, Judy Kirk78, David Cohn79, Jean Herut80, Jon Byron81, James Fiorica82, Amanda E Toland83, Marco Montagna84, Cristina Olia85, Evgeny Imyanitov86, Claudine Isaacs87, Laima Thormorova88, Ignacio Blanco89, Conxi Lazaro90, Alex Teule90, J Del Valle90, Simon A Gayther91, Kunle Odunsi92, Jenny Gross93, Beth Y Karlan93, Ethel Olah94, Soo-Hwang Teo95, Patricia A Ganz96, Mary S Beattie96, Cecelia M Dorling98, Elizabeth Jansen van Rensburg98, Orland Diez99, Ava Kwong100, Rita K Schmutzle101, Barbara Wappenschmidt101, Christoph Engel102, Alfons Meindl103, Nina Ditch104, Norbert Arnold105, Simone Heidemann106, Dieter Niederacher107, Sabine Preissler-Adams108, Dorothea Gadzik109, Raymond Vaen-Mateeva109, Helmut Deissler111, Andrea Gehrig112, Christian Sutter113, Karin Kast114, Britta Fiebig115, Dieter Schäfer116, Trinidad Caldas117, Miguel de la Hoya117, Heli Nevanlinna118, Taru A Muranen118, Bernard Lespérance119, Amanda B Spurdle120, Susan L Neuhausen121, Yuan C Ding121, Xianshu Wang122, Zachary Fredericksen123, Vernon S Pankratz123, Nara Mal Lindo124, Paolo Peterlongo125, Sianoush Manoukian126, Bernard Peissel126, Daniela Zaffaroni126, Bernardo Bonanni127, Loris Bernard128, Riccardo Dolcetti129, Laura Papi130, Laura Ottini131, Paolo Radice132, Mark H Greene132, Jennifer T Loud132, Irene L Andrulis133, Hilmi Ozcelik134, Anna Marie Mulligan135, Gerd Glendon136, Mads Thomassen137, Anne-Marie Gerdes138, Uffe J Jensen139, Anne-Bine Skjæveland140, Torben A Kruse141, Georgia Chenevix-Trench142, Fergus J Couch143, Jacques Simard144, and Douglas F Easton145 and for CIMBA, SWE-BRCA6 and for HEBON30 and for EMBRACE1 and for GEMO Study Collaborators62, for kConFab Investigators120

* Correspondence: antonis@srl.cam.ac.uk
1Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
Full list of author information is available at the end of the article

© 2012 Antoniou et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Introduction: Several common alleles have been shown to be associated with breast and/or ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Recent genome-wide association studies of breast cancer have identified eight additional breast cancer susceptibility loci: rs1011970 (9p21, CDKN2A/B), rs10995190 (ZNF365), rs704010 (ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2).

Methods: To evaluate whether these single nucleotide polymorphisms (SNPs) are associated with breast cancer risk for BRCA1 and BRCA2 carriers, we genotyped these SNPs in 12,599 BRCA1 and 7,132 BRCA2 mutation carriers and analysed the associations with breast cancer risk within a retrospective likelihood framework.

Results: Only SNP rs10771399 near PTHLH was associated with breast cancer risk for BRCA1 mutation carriers (per-allele hazard ratio (HR) = 0.87, 95% CI: 0.81 to 0.94, P-trend = 3 × 10⁻⁷). The association was restricted to mutations proven or predicted to lead to absence of protein expression (HR = 0.82, 95% CI: 0.74 to 0.90, P-trend = 3.1 × 10⁻⁷, P-difference = 0.03). Four SNPs were associated with the risk of breast cancer for BRCA2 mutation carriers: rs10995190, P-trend = 0.015; rs1011970, P-trend = 0.048; rs614367, 2df-P = 0.007; rs1292011 2df-P = 0.03. rs10771399 (PTHLH) was predominantly associated with estrogen receptor (ER)-negative breast cancer for BRCA1 mutation carriers (HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 4 × 10⁻⁵) and there was marginal evidence of association with ER-negative breast cancer for BRCA2 mutation carriers (HR = 0.78, 95% CI: 0.62 to 1.00, P-trend = 0.049).

Conclusions: The present findings, in combination with previously identified modifiers of risk, will ultimately lead to more accurate risk prediction and an improved understanding of the disease etiology in BRCA1 and BRCA2 mutation carriers.

Introduction

Pathogenic mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancers [1,2]. Several lines of evidence suggest that these risks are modified by other genetic or environmental factors that cluster in families. Direct evidence for genetic modifiers of risk has been provided through studies that investigated the associations between common breast and ovarian cancer susceptibility variants, identified through genome-wide association studies (GWAS) or candidate gene studies in the general population, and cancer risk for BRCA1 and BRCA2 carriers. The associations of these eight loci with breast cancer were studied in a GWAS that included mainly cases with two primary breast cancers or a family history of the disease, SNP rs865686 at 9q31.2 was found to be associated with risk for breast cancer, OR = 0.89 (95% CI: 0.85 to 0.92), but no estimates by ER status were reported [17].

The associations of these eight loci with breast cancer risk for BRCA1 and BRCA2 mutation carriers are still unknown. To evaluate these associations, we genotyped the eight SNPs in BRCA1 and BRCA2 mutation carriers participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We further investigated the associations with the risks of developing ER-positive and ER-negative breast cancer and the risk of ovarian cancer.
Materials and methods

Subjects
All carriers participated in clinical or research studies at the host institutions which have been approved by local ethics committees (list provided in Additional file 1 Table S1). Informed consent was obtained from all study participants. Subjects were BRCA1 and BRCA2 mutation carriers recruited by 40 study centres in 28 countries through CIMBA (Additional file 1 Table 2). The majority of carriers (97.58%) were recruited through cancer genetics clinics offering genetic testing, and enrolled into national or regional studies. Some carriers were identified by population-based sampling of cases (2.38%), and some by community recruitment (0.04%). Eligibility to participate in CIMBA is restricted to female carriers of pathogenic BRCA1 or BRCA2 mutations age 18 years old or older at recruitment. Information collected included the year of birth; mutation description, including nucleotide position and base change; self reported ethnic ancestry, age at last follow-up; ages at breast or ovarian cancer diagnoses; and age or date at bilateral prophylactic mastectomy and oophorectomy. Related individuals were identified through a unique family identifier. Women were included in the analysis if they carried mutations that were pathogenic according to generally recognized criteria [18]. Further details on CIMBA can be found elsewhere [19].

Women who carried pathogenic mutations in both BRCA1 and BRCA2 were excluded from the current analysis. The primary analysis was restricted to women self-reported as “white of European ancestry”. The number of mutation carriers of non-white ancestry was too small to allow separate analysis. We investigated possible overlap of carriers between studies by comparing the year of birth, exact mutation description and the reported ages, to identify potential duplicate individuals. Where possible we also used other genotype data on SNPs genotyped in the current round (at least 26 SNPs), in previous genotyping rounds or as part of GWAS to find hidden duplicates. When a potential duplicate was identified, we contacted the relevant centres for further information about these individuals, in a manner that protected the identity of the individuals in question, in order to determine precisely the extent of true overlap in subjects and families appearing more than once in the data set. Duplicate mutation carriers were included only once in the analysis. When in doubt, and when centres could not clarify a potential duplication, one of the samples was excluded from the analysis.

Genotyping
DNA samples (in almost all cases, obtained from blood) were genotyped using the iPLEX Mass Array platform at four genotyping centres (Additional file 1 Table S2); the iPLEX included 26 SNPs as part of a larger study. All centres included at least 2% of the samples in duplicate, no template controls in every plate, and a random mixture of affected and unaffected carriers. Samples that failed for ≥ 20% of all the SNPs typed (that is, five or more) were excluded from the analysis. A study was included in the analysis only if the call rate was over 95%, after samples that failed at multiple SNPs had been excluded. For each study, genotypes for at least 98% of the duplicate samples had to be concordant. To assess the accuracy of genotyping across genotyping centres, the four centres genotyped 95 DNA samples from a standard test plate (Coriell Institute) for all SNPs. If the genotyping was inconsistent for more than one sample in the test plate, all the studies genotyped at the centre were excluded from the analysis of that SNP. No SNPs failed this criterion. The present study included eight SNPs: rs1011970 (9p21, near CDKN2A/B), rs10995190 (10q21, near ZNF365), rs704010 (10q22, near ZMIZ1), rs2380205 (10p15), rs614367 (11q13), rs1292011 (12q24), rs10771399 (12p11 near PTHLH) and rs865686 (9q31.2). Based on the quality control criteria, 4 studies were excluded from the analysis of rs2380205 (one due to low duplicate concordance, 3 due to low call rate), 2 studies were excluded from the analysis of rs704010 (low call rate) and 13 studies were excluded from the analysis of rs1292011 (all due to low call rates). As an additional genotyping quality-control check, we also evaluated the deviation from Hardy-Weinberg equilibrium (HWE) for unrelated subjects separately for each SNP and study. Nine studies had HWE P-values in the range 0.005 to 0.05 (two studies for rs10995190, two studies for rs704010, one study for rs10771399, two for rs1292011 and two for rs865686). Upon examination of the cluster plots for these studies and SNPs, none revealed any unusual patterns and these studies were included in all the analyses. After the above exclusions, a total of 19,731 unique mutation carriers (12,599 BRCA1 and 7,132 BRCA2) from 40 studies had an observed genotype for at least 1 of the SNPs and were included in the primary analysis.

Statistical analysis
The aim of the primary analysis was to evaluate the association between each genotype and breast cancer risk within a survival analysis framework. The time variable for each individual was defined to be the time to breast cancer diagnosis. Each individual was followed until the first breast cancer diagnosis, ovarian cancer diagnosis, or bilateral prophylactic mastectomy or the age at last observation. Only those with a first breast cancer diagnosis were considered as affected in the
analysis. Mutation carriers censored at ovarian cancer diagnosis were considered unaffected. Analysis was conducted by modelling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes as previously described [18]. The effect of each SNP was modelled either as a per-allele hazard ratio (HR) (multiplicative model) or as separate HRs for heterozygotes and homozygotes, and these estimates were on the logarithmic scale. The HRs were assumed to be independent of age (that is, we used a Cox proportional-hazards model). The assumption of proportional hazards was tested by adding a “genotype x age” interaction term to the model in order to fit models in which the HR changed with age. Analyses were carried out with the pedigree-analysis software MENDEL [20]; details of this approach have been described previously [18,21]. We examined between-study heterogeneity by comparing the models that allowed for study-specific log-hazard ratios against models in which the same log-hazard ratio was assumed to apply to all studies.

To investigate whether our results were influenced by any of our assumptions we performed additional sensitivity analyses. If a SNP is associated with disease survival, the inclusion of prevalent cases may influence the HR estimates. Current data indicate that five-year survival after a breast cancer diagnosis is over 80% (Cancer Research - UK, Breast cancer survival statistics) and studies have suggested no difference in survival between mutation carriers and non-carriers [22]. We, therefore, repeated our analysis by excluding mutation carriers diagnosed more than five years prior to recruitment into the study. To examine whether SNP associations differed by type of mutation, we classified BRCA1 mutations according to their potential functional effect [23-26]. Class 1 mutations were those likely to lead to the absence of protein expression due to i) reduced transcript level and/or degradation or instability of truncated proteins, or ii) absence of transcription. Class 1 mutations comprise truncating mutations expected to trigger nonsense-mediated mRNA decay (NMD) or translation re-initiation but no production of stable protein, and deletion of transcription regulatory regions. Class 2 mutations were those likely to generate stable mutant proteins with partial or total loss of function that might also have dominant negative effect. Class 2 mutations include missense substitutions, in-frame deletions and insertions, as well as truncating mutations with premature stop codons occurring in the last exon. Mutations whose consequences at transcript or protein level could not be inferred were not considered for this classification. These were mainly mutations located in splice sites but not characterised for their effect at the transcript level, or large deletions or insertions with undetermined boundaries.

The associations of these SNPs with ovarian cancer risk were evaluated within a competing risk analysis framework [8,9,21], by estimating HRs simultaneously for breast and ovarian cancers. In this model, each individual was at risk of developing either breast or ovarian cancer, by assuming that the probabilities of developing each disease were independent conditional on the underlying genotype. A different censoring process was used for the competing risk analysis, whereby individuals were followed up to the age of the first breast or ovarian cancer diagnosis and were considered to have developed the corresponding disease. No follow-up was considered after the first cancer diagnosis. Individuals were censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of bilateral oophorectomy and were assumed to be unaffected for the corresponding disease. The remaining individuals were censored at the age at last observation and were assumed to be unaffected for both diseases.

We further evaluated the associations of these SNPs with breast cancer subtypes defined by the estrogen receptor (ER) status of the tumours in BRCA1 and BRCA2 mutation carriers. The analysis was carried out by an extension of the retrospective likelihood approach to model the simultaneous effect of each SNP on more than one tumour subtype [14]. Briefly, this involves modelling the conditional likelihood of the observed SNP genotypes and tumour subtypes, given the disease phenotypes. Within this framework it is possible to estimate simultaneously the HRs for each tumour subtype and test for heterogeneity in the associations. Only studies that provided tumour pathology information and had genotype information were included in the analysis. To maximise the available information, genotyped mutation carriers that were missing information on tumour characteristics (within each study) were included in the analysis, and their disease subtype was assumed to be missing at random [14]. This is a reasonable assumption given that more than 90% of mutation carriers in our sample were recruited prior to 2007, when it was uncommon to use tumour pathology in selecting individuals for BRCA1 and BRCA2 mutation screening.

To ensure a sufficiently large number of mutation carriers within each stratum, we grouped studies from the same country. All analyses were stratified by country of residence and used calendar-year- and cohort-specific cancer incidences for BRCA1 and BRCA2 [27]. For sensitivity analyses, strata with small numbers of mutation carriers were grouped. We used a robust variance-estimation approach to allow for the non-independence among related carriers [28].

**Results**

The analysis included 12,599 BRCA1 and 7,132 BRCA2 mutation carriers who were genotyped successfully for...
at least one of the eight SNPs. Table 1 summarises the characteristics of the mutation carriers used in the analysis. In evaluating associations with breast cancer, 10,200 mutation carriers had been diagnosed with a first breast cancer diagnosis, 1,869 were censored at an ovarian cancer diagnosis, 561 at age of bilateral prophylactic mastectomy and 7,101 at the age at last observation.

**Associations with cancer risk for BRCA1 mutation carriers**

Of the eight SNPs, only rs10771399 in *PTHLH* was associated with breast cancer risk for BRCA1 mutation carriers ($P$-trend = $3 \times 10^{-4}$, Table 2). The association was consistent with a multiplicative model in which each copy of the minor allele was estimated to confer a HR of 0.87 (95% CI: 0.81 to 0.94). There was no evidence of heterogeneity in the HR estimates across studies ($P$-het = 0.24, Additional file 1 Supplementary Figure 1). There was no evidence that the HRs varied with age ($P = 0.68$). The association remained significant, with a similar HR estimate (HR = 0.85, 95% CI: 0.77 to 0.93, $P$-trend = $6 \times 10^{-4}$, Table 3), when long-term survivors were excluded from the analysis, suggesting no evidence of survival bias. Interestingly, the association was restricted to BRCA1 carriers of Class 1 mutations (HR = 0.82, 95% CI: 0.74 to 0.90, $P$-trend = $3 \times 10^{-5}$, Table 3) with no evidence of association for Class 2 mutation carriers (HR = 1.00, 0.87 to 1.15, $P$-trend = 0.99, $P$-difference between Class 1 and Class 2 = 0.03).

We found no evidence of association between breast cancer risk for BRCA1 mutation carriers and any of the other SNPs under the trend models ($P$-trend > 0.15). There was, however, some suggestion of an association under the genotype specific model for rs865686 (2df $P = 0.06$, Table 2), reflecting a lower HR for heterozygous carriers than for either homozygote genotype. There was marginal evidence of heterogeneity in the HRs across countries for rs704010 and rs865686 ($P$-het = 0.04 for both), but examination of the forest plots revealed that in each case this was mainly due to a single study/country of relatively small sample size, with the majority of the HR estimates being close to 1 (Additional file 1 Supplementary Figure 1). There was no evidence that the HRs varied by age for any of the SNPs ($P > 0.08$ for all).

We further evaluated the SNP associations with breast and ovarian cancer risk simultaneously (Table 4). The associations with breast cancer risk remained

---

**Table 1 Summary characteristics for the 19731 eligible BRCA1 and BRCA2 carriers* used in the analysis**

| Characteristic          | BRCA1 Unaffected | BRCA1 Breast cancer | BRCA2 Unaffected | BRCA2 Breast cancer |
|-------------------------|------------------|---------------------|------------------|---------------------|
| Number                  | 6,209            | 6,390               | 3,322            | 3,810               |
| Person-years follow-up  | 264,903          | 263,068             | 147,053          | 168,201             |
| Median age at censure (IQR) | 42 (34 to 50)   | 40 (34 to 47)       | 43 (34 to 53)    | 43 (37 to 50)       |
| Age at censure, N (%)   |                  |                     |                  |                     |
| < 30                    | 1,189 (19.2)     | 691 (10.8)          | 611 (18.4)       | 306 (8.0)           |
| 30 to 39                | 1,161 (26.8)     | 2,445 (38.3)        | 834 (25.1)       | 1,141 (30.0)        |
| 40 to 49                | 1,765 (28.4)     | 2,191 (34.3)        | 865 (26.0)       | 1,394 (36.6)        |
| 50 to 59                | 1,058 (17.0)     | 812 (12.7)          | 566 (17.0)       | 687 (18.0)          |
| 60 to 69                | 380 (6.1)        | 198 (3.1)           | 302 (9.1)        | 226 (5.9)           |
| 70+                     | 156 (2.5)        | 53 (0.8)            | 144 (4.3)        | 56 (1.5)            |
| Year of birth, N (%)    |                  |                     |                  |                     |
| < 1920                  | 28 (0.5)         | 30 (0.5)            | 23 (0.7)         | 44 (1.2)            |
| 1920 to 1929            | 131 (2.1)        | 196 (3.1)           | 99 (3.0)         | 167 (4.4)           |
| 1930 to 1939            | 369 (5.9)        | 516 (8.1)           | 232 (7.0)        | 430 (11.3)          |
| 1940 to 1949            | 832 (13.4)       | 1,341 (21.0)        | 458 (13.8)       | 896 (23.5)          |
| 1950 to 1959            | 1,409 (22.7)     | 1,989 (31.1)        | 691 (20.8)       | 1,160 (30.5)        |
| 1960 to 1969            | 1,703 (27.4)     | 1,666 (26.1)        | 902 (27.2)       | 868 (22.8)          |
| 1970+                   | 1,737 (28.0)     | 652 (10.2)          | 917 (27.6)       | 245 (6.4)           |
| Mutation Class, N (%)   |                  |                     |                  |                     |
| Class 1$^1$             | 4,063 (65.4)     | 3,878 (60.7)        | 3,114 (93.7)     | 3,520 (92.4)        |
| Class 2$^2$             | 1,780 (28.7)     | 1,973 (30.9)        | 72 (2.2)         | 100 (2.6)           |
| Other                   | 366 (5.9)        | 539 (8.4)           | 136 (4.1)        | 190 (5.0)           |

---

1 IQR: Interquartile Range

2 See methods for definitions

* Carriers of self-reported white European ancestry only.
### Table 2 SNP genotype distributions and associations with breast cancer risk.

| Mutation | Genotype | Unaffected N (%) | Affected* N (%) | HR | 95% CI | P-value |
|----------|----------|------------------|-----------------|----|--------|---------|
| CDK2NA/B - rs1011970 | BRCA1 | GG | 4,318 (69.7) | 4,460 (70.0) | 1 | | |
| | GT | 1,698 (27.4) | 1,719 (27.0) | 1.01 | 0.94 to 1.09 | |
| | TT | 180 (2.9) | 195 (3.1) | 1.11 | 0.91 to 1.35 | |
| | 2-df test | | | | | 0.61 |
| | per allele | | | | | 1.03 | 0.96 to 1.09 | 0.45 |
| | BRCA2 | GG | 2,279 (68.7) | 2,586 (67.9) | 1 | | |
| | GT | 943 (28.4) | 1,098 (28.9) | 1.08 | 0.98 to 1.19 | |
| | TT | 94 (2.8) | 123 (3.2) | 1.23 | 0.95 to 1.59 | |
| | 2-df test | | | | | 0.12 |
| | per allele | | | | | 1.09 | 1.00 to 1.18 | 0.048 |
| ZNF365 - rs10995190 | BRCA1 | GG | 4,394 (70.9) | 4,556 (71.5) | 1 | | |
| | GA | 1,656 (26.7) | 1,662 (26.1) | 0.98 | 0.91 to 1.06 | |
| | AA | 147 (2.4) | 156 (2.5) | 0.98 | 0.79 to 1.20 | |
| | 2-df test | | | | | 0.89 |
| | per allele | | | | | 0.99 | 0.93 to 1.05 | 0.64 |
| | BRCA2 | GG | 2,334 (70.4) | 2,802 (73.7) | 1 | | |
| | GA | 913 (27.5) | 923 (24.3) | 0.86 | 0.78 to 0.96 | |
| | AA | 68 (20.1) | 79 (2.1) | 0.96 | 0.69 to 1.34 | |
| | 2-df test | | | | | 0.019 |
| | per allele | | | | | 0.90 | 0.82 to 0.98 | 0.015 |
| ZMIZ1 - rs704010 | BRCA1 | CC | 2,476 (40.3) | 2,504 (39.8) | 1 | | |
| | CT | 2,814 (45.8) | 2,894 (46.0) | 1.03 | 0.96 to 1.10 | |
| | TT | 855 (13.9) | 888 (14.1) | 1.04 | 0.93 to 1.15 | |
| | 2-df test | | | | | 0.69 |
| | per allele | | | | | 1.02 | 0.97 to 1.07 | 0.42 |
| | BRCA2 | CC | 1,286 (39.3) | 1,443 (38.4) | 1 | | |
| | CT | 1,496 (45.7) | 1,779 (47.3) | 1.07 | 0.97 to 1.18 | |
| | TT | 494 (15.8) | 539 (14.3) | 0.99 | 0.86 to 1.14 | |
| | 2-df test | | | | | 0.32 |
| | per allele | | | | | 1.01 | 0.95 to 1.08 | 0.73 |
| 10p15 - rs2380205 | BRCA1 | CC | 1,609 (32.5) | 1,710 (32.1) | 1 | | |
| | CT | 2,410 (48.7) | 2,625 (49.3) | 1.01 | 0.93 to 1.09 | |
| | TT | 933 (18.8) | 990 (18.6) | 1.02 | 0.92 to 1.13 | |
| | 2-df test | | | | | 0.95 |
| | per allele | | | | | 1.01 | 0.96 to 1.06 | 0.75 |
| | BRCA2 | CC | 1,013 (32.8) | 1,163 (31.8) | 1 | | |
| | CT | 1,516 (49.1) | 1,816 (49.7) | 1.05 | 0.95 to 1.16 | |
| | TT | 560 (18.1) | 681 (18.6) | 1.03 | 0.90 to 1.17 | |
| | 2-df test | | | | | 0.63 |
| | per allele | | | | | 1.02 | 0.96 to 1.09 | 0.57 |
| 11q13 - rs614367 | BRCA1 | CC | 4,516 (73.2) | 4,581 (72.1) | 1 | | |
| | CT | 1,511 (24.5) | 1,618 (25.5) | 1.05 | 0.98 to 1.14 | |
| | TT | 146 (2.4) | 154 (2.4) | 1.07 | 0.87 to 1.32 | |
| | 2-df test | | | | | 0.34 |
| | per allele | | | | | 1.05 | 0.98 to 1.12 | 0.15 |
| | BRCA2 | CC | 2,432 (73.6) | 2,723 (71.8) | 1 | | |

*Antoniou et al. Breast Cancer Research 2012, 14:R33 http://breast-cancer-research.com/content/14/1/R33*
essentially unchanged in the competing risk analysis, with only the *PTHLH* SNP rs10771399 being significantly associated with breast cancer risk. There was some suggestion of a possible association between this SNP and ovarian cancer risk for *BRCA1* mutation carriers with risk in the opposite direction (HR for ovarian cancer = 1.14, 95% CI: 1.00 to 1.30, *P*-trend = 0.06) especially among rare homozygotes (ovarian cancer HR for GG = 1.67, 95% CI: 1.05 to 2.64, *P*-homozygotes = 0.03). This analysis also provided some weak evidence for an association between SNP rs614367 at 11q13 and ovarian cancer risk for *BRCA1* mutation carriers under the genotype-specific model (2df *P*-value = 0.03). There was no evidence that any of the other SNPs are associated with ovarian cancer risk for *BRCA1* mutation carriers.

**Associations with cancer risk for BRCA2 mutation carriers**

There was evidence of association with breast cancer risk for *BRCA2* mutation carriers for four SNPs (Table 2). The minor allele of rs10995190 in ZNF365 was associated with a reduced risk of breast cancer, where each copy of allele "A" was estimated to confer a HR of 0.90 (95% CI: 0.82 to 0.98, *P*-trend = 0.015). There was also

| Table 2 SNP genotype distributions and associations with breast cancer risk. (Continued) |
|---------------------------------|--------------------------------|------------------|-----------------|-------------------------------|----------------------|------------------|
|                                | CT                        | TT                | 2-df test       | per allele        | 2-df test       | per allele       |
|                                | 799 (24.1) | 983 (26.0) | 0.96 to 1.17 | 0.96 to 1.17 | 0.96 to 1.17 | 0.96 to 1.17 |
|                                | 76 (2.3)  | 83 (2.2)  | 0.72 to 1.30 | 0.72 to 1.30 | 0.72 to 1.30 | 0.72 to 1.30 |
|                                | 0.54                   | 0.54               | 0.54             |
| 12q24 - rs1292011               |                          |                    |                  |                  |                  |                  |
| **BRCA1**                       | AA                       | 1,292 (34.3) | 1,331 (35.4) | 1                |                    |                  |
|                                | 1,825 (48.4) | 1,775 (47.3) | 0.89 to 1.07 | 0.89 to 1.07 | 0.89 to 1.07 | 0.89 to 1.07 |
|                                | 653 (17.3) | 649 (17.3) | 0.90 to 1.14 | 0.90 to 1.14 | 0.90 to 1.14 | 0.90 to 1.14 |
|                                | 1.01                  | 1.01                | 1.01             |
| **BRCA2**                       | AA                       | 824 (35.2) | 908 (35.9) | 0.94 to 1.06 | 0.94 to 1.06 | 0.94 to 1.06 |
|                                | 1,095 (46.7) | 1,225 (48.4) | 0.92 to 1.16 | 0.92 to 1.16 | 0.92 to 1.16 | 0.92 to 1.16 |
|                                | 423 (18.1) | 397 (15.7) | 0.75 to 1.15 | 0.75 to 1.15 | 0.75 to 1.15 | 0.75 to 1.15 |
|                                | 0.84                  | 0.84                | 0.84             |
|                                | 0.03                  | 0.03                | 0.03             |
| **PTHLH - rs10771399**          |                          |                    |                  |                  |                  |                  |
| **BRCA1**                       | AA                       | 4,913 (79.4) | 5,221 (82.0) | 1                |                    |                  |
|                                | 1,194 (19.3) | 1,082 (17.0) | 0.80 to 0.95 | 0.80 to 0.95 | 0.80 to 0.95 | 0.80 to 0.95 |
|                                | 83 (1.3)  | 65 (1.0)  | 0.67 to 1.00 | 0.67 to 1.00 | 0.67 to 1.00 | 0.67 to 1.00 |
|                                | 1.5 × 10^-3 | 1.5 × 10^-3 | 1.5 × 10^-3 | 1.5 × 10^-3 | 1.5 × 10^-3 | 1.5 × 10^-3 |
|                                | 0.97                  | 0.97                | 0.97             |
|                                | 0.10                  | 0.10                | 0.10             |
| **BRCA2**                       | AA                       | 2,649 (80.0) | 3,085 (81.2) | 1                |                    |                  |
|                                | 620 (18.7) | 679 (17.9) | 0.85 to 1.07 | 0.85 to 1.07 | 0.85 to 1.07 | 0.85 to 1.07 |
|                                | 45 (1.4)  | 34 (0.9)  | 0.47 to 1.15 | 0.47 to 1.15 | 0.47 to 1.15 | 0.47 to 1.15 |
|                                | 0.94                  | 0.94                | 0.94             |
|                                | 0.20                  | 0.20                | 0.20             |
| **9q31.2 - rs865686**           |                          |                    |                  |                  |                  |                  |
| **BRCA1**                       | TT                       | 2,521 (40.1) | 2,640 (41.4) | 1                |                    |                  |
|                                | 2,872 (46.4) | 2,849 (44.7) | 0.88 to 1.01 | 0.88 to 1.01 | 0.88 to 1.01 | 0.88 to 1.01 |
|                                | 799 (12.9) | 880 (13.8) | 0.95 to 1.17 | 0.95 to 1.17 | 0.95 to 1.17 | 0.95 to 1.17 |
|                                | 0.06                  | 0.06                | 0.06             |
|                                | 1.00                  | 1.00                | 1.00             |
| **BRCA2**                       | TT                       | 1,277 (38.6) | 1,581 (41.6) | 1                |                    |                  |
|                                | 1,610 (48.6) | 1,717 (45.2) | 0.78 to 0.95 | 0.78 to 0.95 | 0.78 to 0.95 | 0.78 to 0.95 |
|                                | 425 (12.8) | 501 (13.2) | 0.84 to 1.11 | 0.84 to 1.11 | 0.84 to 1.11 | 0.84 to 1.11 |
|                                | 7.3 × 10^-3 | 7.3 × 10^-3 | 7.3 × 10^-3 | 7.3 × 10^-3 | 7.3 × 10^-3 | 7.3 × 10^-3 |
|                                | 0.95                  | 0.95                | 0.95             |
|                                | 0.10                  | 0.10                | 0.10             |

* Breast Cancer
HR, hazard ratio
Table 3 Associations with breast cancer risk, after excluding prevalent breast cancer cases, and BRCA1 mutation class.

|                      | Unaffected, N | Affected, N | HR   | 95% CI       | P-value |
|----------------------|---------------|-------------|------|--------------|---------|
| **Excluding prevalent breast cancer cases** |               |             |      |              |         |
| CDK2NA/B - rs1011970 |               |             |      |              |         |
| BRCA1                | 6,200         | 3,152       | 1.05 | 0.98 to 1.14 | 0.18    |
| BRCA2                | 3,319         | 1,950       | 1.10 | 1.00 to 1.22 | 0.05    |
| ZNF365 - rs10995190 |               |             |      |              |         |
| BRCA1                | 6,201         | 3,151       | 0.96 | 0.89 to 1.04 | 0.34    |
| BRCA2                | 3,318         | 1,949       | 0.90 | 0.81 to 1.00 | 0.05    |
| ZMIZ1 - rs704010     |               |             |      |              |         |
| BRCA1                | 6,149         | 3,094       | 1.02 | 0.96 to 1.08 | 0.53    |
| BRCA2                | 3,276         | 1,919       | 0.98 | 0.91 to 1.06 | 0.64    |
| 10p15 - rs2380205    |               |             |      |              |         |
| BRCA1                | 4,955         | 2,764       | 1.02 | 0.95 to 1.08 | 0.64    |
| BRCA2                | 3,092         | 1,884       | 1.00 | 0.93 to 1.08 | 0.92    |
| 11q13 - rs614367     |               |             |      |              |         |
| BRCA1                | 6,177         | 3,144       | 1.01 | 0.94 to 1.10 | 0.73    |
| BRCA2                | 3,310         | 1,944       | 0.99 | 0.89 to 1.10 | 0.88    |
| 12q24 - rs1292011    |               |             |      |              |         |
| BRCA1                | 3,773         | 1,798       | 1.04 | 0.97 to 1.12 | 0.29    |
| BRCA2                | 2,345         | 1,220       | 0.96 | 0.88 to 1.06 | 0.41    |
| PTHLH - rs10771399   |               |             |      |              |         |
| BRCA1                | 6,194         | 3,152       | 0.85 | 0.77 to 0.93 | 5.8 × 10^{-4} |
| BRCA2                | 3,317         | 1,944       | 0.89 | 0.78 to 1.00 | 0.06    |
| 9q31.2 - rs865686    |               |             |      |              |         |
| BRCA1                | 6,196         | 3,149       | 1.01 | 0.95 to 1.07 | 0.72    |
| BRCA2                | 3,315         | 1,946       | 0.94 | 0.87 to 1.02 | 0.15    |
| **BRCA1 analysis by mutation class** |               |             |      |              |         |
| CDK2NA/B - rs1011970 |               |             |      |              |         |
| Class1               | 4,040         | 3,843       | 1.01 | 0.94 to 1.10 | 0.72    |
| Class2               | 1,771         | 1,958       | 1.03 | 0.91 to 1.16 | 0.66    |
| ZNF365 - rs10995190  |               |             |      |              |         |
| Class1               | 4,058         | 3,844       | 0.99 | 0.92 to 1.07 | 0.80    |
| Class2               | 1,774         | 1,957       | 0.97 | 0.86 to 1.09 | 0.59    |
| ZMIZ1 - rs704010     |               |             |      |              |         |
| Class1               | 3,998         | 3,787       | 1.04 | 0.98 to 1.10 | 0.22    |
| Class2               | 1,767         | 1,956       | 1.01 | 0.92 to 1.11 | 0.85    |
| 10p15 - rs2380205    |               |             |      |              |         |
| Class1               | 3,664         | 3,538       | 1.01 | 0.95 to 1.07 | 0.82    |
| Class2               | 931           | 1,263       | 1.03 | 0.91 to 1.15 | 0.67    |
| 11q13 - rs614367     |               |             |      |              |         |
| Class1               | 4,024         | 3,833       | 1.10 | 1.02 to 1.19 | 0.02    |
| Class2               | 1,764         | 1,948       | 0.94 | 0.84 to 1.06 | 0.32    |
| 12q24 - rs1292011    |               |             |      |              |         |
| Class1               | 2,812         | 2,521       | 0.99 | 0.92 to 1.06 | 0.71    |
| Class2               | 642           | 797         | 0.97 | 0.84 to 1.12 | 0.68    |
| PTHLH - rs10771399   |               |             |      |              |         |
| Class1               | 4,035         | 3,841       | 0.82 | 0.74 to 0.90 | 3.1 × 10^{-5} |
| Class2               | 1,770         | 1,953       | 1.00 | 0.87 to 1.15 | 0.99    |
| 9q31.2 - rs865686    |               |             |      |              |         |
| Class1               | 4,038         | 3,840       | 0.98 | 0.92 to 1.04 | 0.48    |
| Class2               | 1,769         | 1,957       | 1.03 | 0.94 to 1.14 | 0.49    |

HR, hazard ratio
Table 4 Competing risk analysis*.

| CDK2NA/B - rs1011970 | Unaffected N (%) | Breast cancer N (%) | Ovarian cancer N (%) | HR 95% CI | P-value HR 95% CI | P-value |
|-----------------------|------------------|---------------------|---------------------|-----------|-------------------|---------|
| BRCA1                 | 3,328 (69.6)     | 4,424 (69.9)        | 1,026 (70.1)        | 1         | 1.09 to 1.11      | 1.10    |
|                       | 1,309 (27.4)     | 1,710 (27.0)        | 398 (27.2)          | 1.03      | 0.88 to 1.35      | 0.90    |
|                       | 142 (3.0)        | 194 (3.1)           | 39 (2.7)            | 1.09      | 0.91 to 1.11      | 0.90    |
| 2-df test             |                  | 0.57                |                     | 0.35      |                   |         |
| per allele            |                  | 0.30                |                     | 0.48      |                   |         |
| BRCA2                 | 1,972 (68.6)     | 2,578 (67.9)        | 315 (69.5)          | 1         | 1.09 to 1.11      | 1.07    |
|                       | 815 (28.4)       | 1,097 (28.9)        | 129 (28.5)          | 1.09      | 0.91 to 1.57      | 0.84    |
|                       | 86 (3.0)         | 122 (3.2)           | 9 (2.0)             | 1.09      | 0.91 to 1.57      | 1.10    |
| 2-df test             |                  | 0.15                |                     | 0.74      |                   |         |
| per allele            |                  | 0.90                |                     | 0.90      |                   |         |
| ZNF365 - rs10995190   | 3,408 (71.3)     | 4,523 (71.5)        | 1,019 (69.6)        | 1         | 1.00 to 1.08      | 1.00    |
|                       | 1,258 (26.3)     | 1,650 (26.1)        | 410 (28.0)          | 0.96      | 0.78 to 1.20      | 0.90    |
|                       | 113 (2.4)        | 155 (2.5)           | 35 (2.4)            | 1.09      | 0.93 to 1.06      | 0.90    |
| 2-df test             |                  | 0.94                |                     | 0.23      |                   |         |
| per allele            |                  | 0.88                |                     | 0.32      |                   |         |
| BRCA2                 | 2,033 (70.4)     | 2,795 (73.7)        | 318 (70.2)          | 1         | 1.00 to 1.06      | 1.06    |
|                       | 794 (27.7)       | 920 (24.3)          | 122 (26.9)          | 1.03      | 0.74 to 1.43      | 1.58    |
|                       | 55 (1.9)         | 79 (2.1)            | 13 (2.9)            | 1.03      | 0.74 to 1.43      | 1.58    |
| 2-df test             |                  | 0.02                |                     | 0.37      |                   |         |
| per allele            |                  | 0.03                |                     | 0.55      |                   |         |
| ZMIZ1 - rs704010      | 1,904 (40.2)     | 2,493 (40.0)        | 583 (40.1)          | 1         | 1.00 to 1.10      | 1.01    |
|                       | 2,172 (45.9)     | 2,871 (46.0)        | 665 (45.7)          | 1.02      | 0.92 to 1.14      | 1.01    |
|                       | 660 (13.9)       | 877 (14.1)          | 206 (14.2)          | 1.02      | 0.93 to 1.08      | 1.01    |
| 2-df test             |                  | 0.67                |                     | 0.99      |                   |         |
| per allele            |                  | 0.58                |                     | 0.90      |                   |         |
| BRCA2                 | 1,109 (39.0)     | 1,439 (38.4)        | 181 (40.1)          | 1         | 1.00 to 1.07      | 1.01    |
|                       | 1,306 (46.0)     | 1,774 (47.3)        | 192 (43.4)          | 1.06      | 0.86 to 1.15      | 1.06    |
|                       | 426 (15.0)       | 538 (14.3)          | 69 (15.6)           | 1.03      | 0.96 to 1.17      | 1.05    |
| 2-df test             |                  | 0.46                |                     | 0.81      |                   |         |
| per allele            |                  | 0.72                |                     | 0.90      |                   |         |
| 10p15 - rs2380205     | 1,183 (32.2)     | 1,698 (32.1)        | 438 (33.2)          | 1         | 1.00 to 1.12      | 1.00    |
|                       | 1,796 (48.9)     | 2,605 (49.3)        | 634 (48.1)          | 0.99      | 0.90 to 1.12      | 0.94    |
|                       | 696 (18.9)       | 981 (18.6)          | 246 (18.7)          | 1.00      | 0.91 to 1.08      | 0.91    |
| 2-df test             |                  | 0.96                |                     | 0.45      |                   |         |
| per allele            |                  | 0.98                |                     | 0.40      |                   |         |
| BRCA2                 | 872 (32.6)       | 1,161 (31.8)        | 143 (33.7)          | 1         | 1.00 to 1.06      | 1.00    |
|                       | 1,321 (49.4)     | 1,812 (49.6)        | 199 (46.9)          | 1.04      | 0.94 to 1.16      | 0.94    |
|                       | 481 (18.0)       | 678 (18.6)          | 82 (19.3)           | 1.03      | 0.90 to 1.18      | 1.01    |
| 2-df test             |                  | 0.74                |                     | 0.82      |                   |         |
| per allele            |                  | 0.61                |                     | 0.98      |                   |         |
| 11q13 - rs614367      | 3,439 (72.3)     | 4,547 (72.1)        | 1,111 (76.2)        | 1         | 1.00 to 1.12      | 1.00    |
|                       | 1,212 (25.5)     | 1,606 (25.5)        | 311 (21.3)          | 1.02      | 0.94 to 1.11      | 0.83    |
|                       | 109 (2.3)        | 154 (2.4)           | 37 (2.5)            | 1.12      | 0.91 to 1.39      | 1.20    |
| 2-df test             |                  | 0.52                |                     | 0.03      |                   |         |
some marginal evidence that the minor allele of rs1011970 near CDKN2A/CDKN2B was associated with increased breast cancer risk (HR = 1.09, 95% CI: 1.00 to 1.18, \( P \)-trend = 0.048). None of the other polymorphisms was associated with breast cancer risk for BRCA2 mutation carriers under the multiplicative model. However, SNPs rs865686 and rs1292011 were associated with risk under the genotype specific model (2df-\( P \) = 0.007 and 0.03 respectively, Table 2). There was some evidence of heterogeneity in the HRs across countries for rs1011970 (\( P \)-het = 0.005). This appeared to be mainly due to the USA stratum. The heterogeneity was no longer significant after removal of that stratum (\( P \)-het = 0.42) and the HR estimate for the association with breast cancer risk increased to 1.20 (95% CI: 1.09 to 1.32, \( P \)-trend = 1 \( \times \) 10\(^{-4} \)). There was no heterogeneity for any of the other SNPs (\( P \)-het > 0.12 for all, Additional file 1 Supplementary Figure 2). The HR estimates

| SNP             | Gene    | Allele 1 | Allele 2 | Allele 3 | Frequency | Hazard Ratio | 95% CI      | 2-df \( P \) | 12q24 - rs1292011 |
|-----------------|---------|----------|----------|----------|-----------|--------------|------------|-------------|------------------|
| CDKN2A/CDKN2B   |         | rs1011970|          |          | 1,03      | 0.91 to 1.10 | 0.35       | 0.91        | 0.80 to 1.03     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.62      |              | 0.84       |             |                  |
|                 |         |          |          |          | 1.03      | 0.94 to 1.12 | 0.56       | 0.94        | 0.77 to 1.15     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.43      |              |            |             |                  |
| BRCA2           |         | rs1292011|          |          | 1.03      | 0.91 to 1.10 | 0.35       | 0.91        | 0.80 to 1.03     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.62      |              | 0.84       |             |                  |
|                 |         |          |          |          | 1.03      | 0.94 to 1.12 | 0.56       | 0.94        | 0.77 to 1.15     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.43      |              |            |             |                  |
| BRCA1           |         | rs10771399|        |          | 1.03      | 0.91 to 1.10 | 0.35       | 0.91        | 0.80 to 1.03     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.62      |              | 0.84       |             |                  |
|                 |         |          |          |          | 1.03      | 0.94 to 1.12 | 0.56       | 0.94        | 0.77 to 1.15     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.43      |              |            |             |                  |
| PTHLH           |         | rs865686 |          |          | 1.03      | 0.91 to 1.10 | 0.35       | 0.91        | 0.80 to 1.03     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.62      |              | 0.84       |             |                  |
|                 |         |          |          |          | 1.03      | 0.94 to 1.12 | 0.56       | 0.94        | 0.77 to 1.15     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.43      |              |            |             |                  |
| BRCA2           |         | rs865686 |          |          | 1.03      | 0.91 to 1.10 | 0.35       | 0.91        | 0.80 to 1.03     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.62      |              | 0.84       |             |                  |
|                 |         |          |          |          | 1.03      | 0.94 to 1.12 | 0.56       | 0.94        | 0.77 to 1.15     |
|                 |         |          |          |          |           |              |            |             |                  |
|                 |         |          |          |          | 1         |              |            |             |                  |
|                 |         |          |          |          | 0.43      |              |            |             |                  |
for the four associated SNPs were similar when long-term survivors were excluded from the analysis (Table 3). Consistent with the results of the main analysis, rs10995190 in ZNF365 and rs1011970 near CDKN2A/CDKN2B provided marginal evidence of association using the trend-test statistic (P-trend = 0.05 for both) and SNPs rs865686 was associated with breast cancer risk under the genotype specific model (2df-P = 0.03). SNP rs1292011 was not associated with breast cancer risk in this analysis. A somewhat smaller HR estimate was obtained for the PTHLH SNP rs10771399 compared to the main analysis (per-allele HR = 0.89, 95% CI: 0.78 to 1.00, P-trend = 0.06). The attenuation of the association in the overall analysis could have occurred if the SNP is also associated with prognosis. However, the difference in the HRs was small. The results for the remaining SNPs were similar and non-significant. None of SNPs were associated with ovarian cancer risk for BRCA2 mutation carriers (Table 4).

### Associations by tumour ER-status

Table 5 summarises the associations of the eight SNPs with breast cancer ER status in BRCA1 and BRCA2 mutation carriers. Only the PTHLH SNP rs10771399 was associated with ER-negative breast cancer for BRCA1 mutation carriers (ER-negative HR = 0.81, 95% CI: 0.74 to 0.90, P-trend = 3.8 × 10⁻⁵). There was also marginal evidence that SNP rs704010 near ZMIZ1 was associated with ER-positive breast cancer for BRCA1 mutation carriers (ER-positive HR = 1.12, 95% CI: 1.00 to 1.26, P-trend = 0.046). However, the associations between ER-negative and ER-positive breast cancer among BRCA1 mutation carriers were only significantly different for SNP rs1292011 at 12q24 (P-heterogeneity = 0.045).

Despite the small number of BRCA2 ER-negative breast cancers, there was a suggestion that the minor allele of the PTHLH SNP rs10771399 is protective for ER-negative breast cancer for BRCA2 mutation carriers (HR for ER-negative = 0.78, 95% CI: 0.62 to 1.00, P-

| Table 5 Associations with estrogen receptor-positive and estrogen receptor-negative breast cancer risk for BRCA1 and BRCA2 carriers. |
|-------------------------------------------------|
| Unaffected | ER-positive N | ER-negative N | ER status unknown N | ER-positive | ER-negative |
|-----------|--------------|---------------|---------------------|-------------|-------------|
|           | HR | 95% CI | P-value | HR | 95% CI | P-value | P-dif |
| CDK2NA/B - rs1011970 |
| BRCA1 4,893 | 559 | 1,888 | 2,841 | 0.95 | 0.81 to 1.12 | 0.56 | 1.03 | 0.95 to 1.11 | 0.47 | 0.41 |
| BRCA2 2,928 | 1,372 | 424 | 1,649 | **1.10** | **1.00 to 1.22** | **0.05** | 1.15 | 0.96 to 1.37 | 0.12 | 0.70 |
| ZNF365 - rs10995190 |
| BRCA1 4,895 | 559 | 1,887 | 2,843 | 0.88 | 0.74 to 1.04 | 0.14 | 1.01 | 0.94 to 1.10 | 0.75 | 0.16 |
| BRCA2 2,927 | 1,370 | 406 | 1,648 | **0.89** | **0.80 to 1.00** | **0.043** | 0.87 | 0.71 to 1.07 | 0.19 | 0.84 |
| ZMIZ1 - rs704010 |
| BRCA1 4,842 | 548 | 1,846 | 2,811 | **1.12** | **1.00 to 1.26** | **0.046** | 1.00 | 0.94 to 1.06 | 0.91 | 0.08 |
| BRCA2 2,887 | 1,347 | 401 | 1,636 | 1.01 | 0.93 to 1.09 | 0.91 | 1.00 | 0.87 to 1.14 | 0.95 | 0.91 |
| 10p15 - rs2380205 |
| BRCA1 4,465 | 540 | 1,812 | 2,513 | 0.90 | 0.80 to 1.01 | 0.08 | 1.02 | 0.96 to 1.09 | 0.46 | 0.06 |
| BRCA2 2,701 | 1,341 | 396 | 1,543 | 1.02 | 0.95 to 1.10 | 0.60 | 0.94 | 0.82 to 1.08 | 0.39 | 0.31 |
| 11q13 - rs614367 |
| BRCA1 4,879 | 557 | 1,886 | 2,832 | 1.09 | 0.93 to 1.29 | 0.30 | 1.04 | 0.96 to 1.12 | 0.40 | 0.59 |
| BRCA2 2,921 | 1,365 | 405 | 1,639 | 1.06 | 0.96 to 1.17 | 0.26 | 0.84 | 0.69 to 1.04 | 0.10 | 0.05 |
| 12q24 - rs1292011 |
| BRCA1 3,429 | 308 | 1,043 | 2,031 | 0.87 | 0.74 to 1.02 | 0.09 | 1.05 | 0.98 to 1.13 | 0.12 | **0.046** |
| BRCA2 2,065 | 813 | 239 | 1,170 | 0.95 | 0.86 to 1.04 | 0.28 | 0.98 | 0.82 to 1.16 | 0.78 | 0.79 |
| PTHLH - rs10771399 |
| BRCA1 4,889 | 557 | 1,887 | 2,842 | 0.94 | 0.78 to 1.13 | 0.52 | **0.81** | **0.74 to 0.90** | **3.8 × 10⁻⁵** | 0.20 |
| BRCA2 2,926 | 1,366 | 406 | 1,648 | 0.97 | 0.86 to 1.10 | 0.68 | **0.78** | **0.62 to 1.00** | **0.049** | 0.12 |
| 9q31.2 - rs865686 |
| BRCA1 4,892 | 559 | 1,888 | 2,836 | 0.92 | 0.81 to 1.03 | 0.15 | 1.01 | 0.95 to 1.08 | 0.68 | 0.16 |
| BRCA2 2,924 | 1,370 | 405 | 1,645 | **0.91** | **0.84 to 0.99** | **0.028** | 1.07 | 0.92 to 1.25 | 0.40 | 0.08 |

ER, estrogen receptor; HR, hazard ratio
trend = 0.049), but there was no association with ER-positive breast cancer. There was evidence that SNPs rs10995190 near ZNF365, rs865686 at 9q31.2 and rs1011970 near CDKN2A/B are associated with ER-positive breast cancer for BRCA2 mutation carriers (P-trend = 0.043, 0.028 and 0.05 respectively). However, the HR estimates were not significantly different from those for ER-negative breast cancer.

**Discussion**

We have investigated eight novel breast cancer susceptibility loci identified through breast cancer GWAS [15-17] for their associations with breast cancer risk for BRCA1 and BRCA2 mutation carriers using data from the CIMBA. The estimated per-allele ORs associated with the minor allele of each SNP from the population-based studies varied from 0.85 to 1.15, and only four of the eight SNPs had ORs of less than 0.90 or greater than 1.10 (rs10995190, rs614367, rs865686 and rs10771399) [15-17]. For BRCA1 mutation carriers, only SNP rs10771399 at 12p11 was associated with the overall risk of breast cancer, whereas SNPs rs10995190 at 10q21, rs1011970 at 9q21, rs865686 at 9q31.2 and rs1292011 at 12q24 were associated with breast cancer risk for BRCA2 mutation carriers. The magnitude of the estimated HRs for all these SNPs were consistent with the OR estimates for the risk of breast cancer in the general population. The power to detect associations with SNPs conferring relative risks in the range of 0.90 to 1.10 was limited by our sample size, particularly among BRCA2 mutation carriers [29].

Based on the HR estimates and associated 95% confidence intervals, given our sample size of BRCA1 mutation carriers, it is unlikely that the relative risks for overall BRCA1 breast cancer risk are of similar magnitude to those estimated in the general population for SNPs rs10995190 at 10q21 (estimated odds ratio (OR) from the replication stage of the GWAS = 0.76), rs2380205 at 10p15 (OR = 0.94), rs614367 at 11q13 (OR = 1.15), rs1292011 at 12q24 (OR = 0.92) and rs865686 at 9q31.2 (OR = 0.89), since the 95% confidence intervals for the HRs do not include the estimated OR from the population-based studies. Similarly, the HRs for BRCA2 breast cancer risk exclude the ORs from the general population for SNPs rs2380205 at 10p15 and rs614367 at 11q13. Taken together, these findings suggest that SNPs rs2380205 at 10p15 and rs614367 at 11q13 do not modify breast cancer risk in either BRCA1 or BRCA2 mutation carriers. A replication study by BCAC, involving close to 50,000 breast cancer cases and 50,000 controls, found only weak evidence for association of rs2380205 at 10p15 with breast cancer risk in the general population [Lambrechts and Easton personal communication, manuscript submitted] suggesting that the original finding (OR = 0.94, P = 5 × 10^{-7} [15]) may have been a false positive. If this were true, the absence of an association in carriers would be expected. The lack of evidence for an association with the 11q13 SNP rs614367 with BRCA1 and BRCA2 breast cancer risk is more surprising since the association in the general population is relatively strong and consistently replicated (OR 1.21, 95% CI 1.17 to 1.25 in the recent BCAC analysis [Lambrechts and Easton personal communication, manuscript submitted]). The association in the general population appears to be restricted to ER-positive disease, which would explain the lack of association for BRCA1 carriers but not BRCA2 carriers. This is perhaps the clearest evidence so far of a departure from a multiplicative interaction between a common susceptibility locus and a BRCA2 mutation on the risk of developing breast cancer. The lack of an association in BRCA1 carriers for rs1292011 and rs865686 is also consistent with the observation that these associations are stronger for ER-positive disease in the general population [16]. The absence of an association for ZNF365 rs10995190 in BRCA1 carriers is more surprising since this association appears to be unrelated to ER status in the general population [Lambrechts and Easton personal communication, manuscript submitted] [30].

Of the eight SNPs investigated, the strongest association was found between SNP rs10771399 at 12p11 and breast cancer risk for BRCA1 mutation carriers. Other loci previously found to be associated with BRCA1 breast cancer risk include the 19p13 and 6q25.1 loci [6,9], TOX3 and CASP8 [3,5,7]. Analysis by tumour ER-status revealed that rs10771399 at 12p11 has a stronger association with ER-negative than ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers. The ER-specific HRs were similar for both genes, suggesting that this SNP is primarily associated with ER-negative breast cancer, although results from the general population suggested similar ORs for ER-positive and ER-negative breast cancer (0.87 for ER-positive disease, 0.85 for ER-negative disease [16]). Interestingly, the association among BRCA1 mutation carriers was restricted to those carrying mutations proven or predicted to lead to absence of protein expression (Class 1) with no evidence for an association in carriers of BRCA1 mutations likely to generate stable mutant proteins (Class 2) (P-diff = 0.03). This observation suggests that the modifying effect of SNP rs10771399 at 12p11 might be attenuated for tumours that retain residual BRCA1 function or that retain the capacity to bind to some of its partners. rs10771399 lies in a region at 12p11 that contains PTHLH (parathyroid hormone-like hormone isoform 1, also known as PTHR1 - parathyroid hormone-related protein) and CCDC91. PTHLH is a plausible candidate cancer susceptibility gene. It encodes...
a protein that regulates endochondral bone development and epithelial-mesenchymal interactions during the formation of the mammary glands. The receptor of this hormone, PTHR1, is responsible for most cases of humoral hypercalcemia of malignancy [31]. It is produced by various types of carcinomas [32], and is an important factor in the development of bone metastasis [33].

We found that SNP rs10995190 ZNF365 is associated with BRCA2 breast cancer risk. A different SNP (rs16917302) in ZNF365, which is only weakly correlated with rs10995190 (pairwise $r^2$ is approximately 0.10 in the present sample) was previously identified via a GWAS of breast cancer in BRCA2 mutation carriers [10]. These results suggest that there could be a causal associated variant correlated with both rs10995190 and rs16917302, or alternatively on more than one causal disease variant in this locus. SNP rs10995190 has also recently been found to be associated with mammographic density in the general population [34]. Previous studies found that mammographic density modifies breast cancer risk for BRCA2 mutation carriers [35], raising the possibility that this locus modifies breast cancer risk for BRCA2 mutation carriers through its influence on mammographic density. However, mammographic density has also been shown to modify the breast cancer risk for BRCA1 carriers, which also makes the absence of association for rs10995190 in BRCA1 carriers somewhat surprising. Mammographic density data are not available in the CIMBA sample to test this hypothesis explicitly.

There was no evidence of association with ovarian cancer risk for BRCA1 or BRCA2 mutation carriers for any of the SNPs, with the exception of some weak evidence for SNPs rs10771399 and rs614367 for BRCA1 carriers. This is not surprising, since all SNPs were selected on the basis of prior evidence of association with breast cancer risk in the general population and none of these SNPs have so far been found to be associated with ovarian cancer in general population through the ongoing GWAS [36-38].

Conclusions

The per-allele HRs estimated for each of the associated loci in the present report are modest, and in isolation would have only a small impact on the absolute risks of developing breast cancer. However, we have shown previously that modifier SNPs in combination can result in large differences in the absolute risk of developing breast cancer for carriers at the extreme percentiles of the combined SNP distribution [5,39]. Furthermore, the causal variants underlying these loci may confer larger relative risks. Considering all reported modifying loci by the CIMBA consortium, there are now six loci in total that are associated with breast cancer risk for BRCA1 mutation carriers (19p13, 6q25.1, 12p11, TOX3, 2q35 and CASP8) and 13 loci which are known to be associated with BRCA2 breast cancer risk (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, 1p11.2, ZNF365, CDKN2A/B, 9q31.2, 12q24 and RAD51). Ongoing GWAS in BRCA1 and BRCA2 mutation carriers and in the general population are likely to identify further modifier loci and taken together, they may lead to more accurate risk predictions in mutation carriers with implications for clinical management, and to a better understanding of the biology of tumour development in mutation carriers.

Additional file 1: Supplementary tables and figures. Table S1 List of local ethics committees that granted approval for the access and use of the data in current study. Supplementary figure 1 Forest plot of the country-specific per-allele HR estimates for breast cancer for BRCA1 mutation carriers. Supplementary figure 2 Forest plot of the country-specific per-allele HR estimates for breast cancer for BRCA2 mutation carriers.

Abbreviations

BCAC: Breast Cancer Association Consortium; CIMBA: Consortium of Investigators of Modifiers of BRCA1/2; ER: estrogen receptor; GWAS: genome-wide association studies; HR: hazard ratio; HWE: Hardy-Weinberg equilibrium; NMD: nonsense-mediated mRNA decay; OR: odds ratio; SNPs: single-nucleotide polymorphism.

Acknowledgements

This work was supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. The research leading to these results has received funding from the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175), from the Canadian Institutes of Health Research for the “CIHR Team in Familial Risks of Breast Cancer” program and by the Canadian Breast Cancer Research Alliance-grant #019511. This research was also supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defence Ovarian Cancer Idea award (WB1XWH-10-1-0341) and grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure. ACA is a CR-UK Senior Cancer Research Fellow, DFE is CR-UK Principal Research Fellow, GCT is a NHMRC Senior Principal Research Fellow, J.S. is Chairholder of the Canada Research Chair in Oncogenetics. Study specific Baltic Familial Breast and Ovarian Cancer Consortium

We acknowledge the Genome Database of Latvian Population, Latvian Biomedical Research and Study Centre and Ramunas Janavicius (Minsk University Hospital Santariskiu Clinics, Lithuania) for data and DNA samples for BFBOCC. The work was supported in part by a grant from the European Social Fund Nr.2009/0201/1DP.1.1.1.2.0/09/APIA016. BMBF was supported by grants from the Cancer Association of South Africa (Cansa) to Elizabeth J. van Rensburg.

Breast Cancer Family Registry (BCFR) This work was supported by the National Cancer Institute, National Institutes of Health under RFA-CA-06-503 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), Cancer Prevention Institute of
California (formerly the Northern California Cancer Center) (U01 CA69417), University of Melbourne (U01 CA69638), and Research Triangle Institute Informatics Support Center (RFP No. N02PC45022-46). Samples from the FCCC, HCI and CPIC were processed and distributed by the Coriell Institute for Medical Research. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the BCFR, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government or the BCFR.

CNO

The research leading to these results has been partially funded by Mutua Madrileña Foundation, “Red de Investigación en Cáncer RD06/0020/1160” and Spanish Ministry of Science and Innovation (FIS PI08 1120 and SAF2010-20493).

Copenhagen Breast Cancer Study (IBCS)

We would like to thank Bent Ejertsen for clinical data and acknowledge the INEV Foundation for financial support.

Deutsches Krebsforschungszentrum (DKFZ) study

The DKFZ study was supported by the DKFZ.

Epidemiological study of BRCA1 & BRCA2 mutation carriers (EMBRACE)

Douglas F. Easton is the PI of the study. EMBRACE Collaborating Centres are: Coordinating Centre, Cambridge: Susan Peacock, Debra Frost, Steve D. Ellis, Elena Fenech by appointment. UK Grants C1287/A10118 and C1287/A11900. D. Gareth Evans and Fiona Lalloo are supported by an NIH grant to the Biomedical Research Centre, Manchester. The Investigators at The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust: Ros Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Elizabeth Page, Audrey Ardern-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Anita Mitra, Lisa Robertson. North Trent Clinical Genetics Service, Sheffield: Jackie Cook, Oliver Quarell, Cathryn Bardsley. South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizzie Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard. Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton: Diana Eccles, Anneke Lucassen, Gillian Crawford, Donna McBride, Sarah Smalley. EMBRACE is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11900.

This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and the GOG Tissue Bank (CA 27469) and to the GOG Statistical and Data Center (CA 37517 and CA 101165). We thank the investigators of the Australia New Zealand Gynaecological Oncology Group (ANZGOG). GOG’s participation was sponsored by GOG’s Cancer Prevention and Control Committee, and supported through funding provided by both intramural (Clinical Genetics Branch, DCEG) and extramural (Community Oncology and Prevention Trials Program - COPTPG) NCI programs.

Hospital Clinico San Carlos (HCSC)

The HCSC study was partially supported by Instituto de Salud Carlos III: RD06/0020/0021. We wish to thank Dr. Pedro Perez-Segura and Dr. Atocha Romero for their contribution to this study.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)

HEBON Collaborating Centres: Coordinating center: Netherlands Cancer Institute, Amsterdam, NL: F.B.L. Hogervorst, S. Verhoef, M. Verheus, I.J. van ’t Veer, F.E. van Leeuwen, M.A. Rookus; Erasmus Medical Center, Rotterdam, NL: M. Collée, A.M.W. van den Ouwel, A. Jager, M.J. Hoorning, M.M.A. Tilanus-Linthorst, C. Seynaeve; Leiden University Medical Center, NL: Leiden: C.J. van Asperen, J.T. Wijnen, M.P. Vreewijk, R.A. Tollenaar, P. Devilee; Radboud University Nijmegen Medical Center, Nijmegen, NL: M.J. Ligtenberg, N. Hoogerbrugge; University Medical Center Utrecht, Utrecht, NL: M.G. Ausems, R.B. van der Luijt; Amsterdam Medical Center, NL: CM. Alfons, T.A. van Os; VU University Medical Center, Amsterdam, NL: J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, Maastricht, NL: E.B. Gomez-Garcia, C.E. van Roozendael, Marinus J. Blok, B. Caanen; University Medical Center Groningen University, NL: J.C. Oostervink; A.H. van der Hout; The Netherlands Foundation for the detection of hereditary tumours, Leiden, NL: H.T. Vassen. The HEBON study is supported by the Dutch Cancer Society grants NKI198-1584, NIK0204-3088, NIK0207-3756 and the ZonMW grant 91109024.

Helsinki Breast Cancer Study (HBCS)

HBCS acknowledged Drs. Kristina Artrormaki, Kirmsi Aaltoren and Carl Bloqvist and Tuomas Heikkinen and research nurse Ilja Erkkila for their help with the patient data and samples. The HBCS study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation.

ICO

Contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute and Autonomous Government of Catalonia. Contract grant numbers: ISCIII RETIC RD06/0020/1051, P110/01422, P110/31488 and 2009SGR290.

ILUH

The ILUH group was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landspitali University Hospital Research Fund.

INHERIT

We would like to thank Stéphane Dubois, Dr Martine Dumont, Martine Tranchant (Cancer Genomics Laboratory, CRCHUQ) for sample management and skillful technical assistance, Sylvie Desjardins and Marc-André Rodrigue (Plateforme de séquençage et de génotypage des génome du CRCHU/ CRHUQ) for iPLEX genotyping and Pascal Belleau for data quality control analyses.

Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOVHBCS)

This study was supported by Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) and “Ministero della Salute” (“Progetto Tumori Femminili and grant numbers RPS 2006-5-34133, ACC/8569”).

KConFab

We wish to thank Heather Thorne, Eveline Niedermayer, all the KConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded 2001-2009 by NHMRC and currently by the National Breast Cancer Foundation and Cancer Australia #362833) for their contributions to this project, and the many families who contribute to KConFab. KConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council (NHMRC) and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer
Foundation of Western Australia. ABS is funded by an NHMRC Senior Research Fellowship.
Memorial Sloan-Kettering Cancer Center (MSKCC)
We acknowledge the Starm Cancer Consortium, the Breast Cancer Research Foundation, the Norman and Carol Stone Cancer Research Initiative, the Kate and Robert Niehaus Clinical Cancer Research Initiative, the Lymphoma Foundation, and the Sabin Family Research Initiative.
National Cancer Institute (NCI) The research of Drs. Greene and Loud was supported by the Intramural Research Program of the US National Cancer Institute at the National Institutes of Health, and by support services contracts NO2-CP-11019-50 and NO2-CP-65504 with Westat, Inc, Rockville, MD.
N.N. Petrov Institute of Oncology (NNIPO)
This work has been supported by the Russian Federation for Basic Research (grants 10-04-92601, 10-04-92110, 11-04-00227) and the Federal Agency for Science and Innovations (contract 16.5121.12.2237) and through a Royal Society International Joint grant (JP00615).
The Hong Kong Hereditary Breast Cancer Family Registry thank Dr. Ellen Li
Charitable Foundation for their support
Hungarian Breast and Ovarian Cancer Study (HUNBOCS)
The study was supported by Norwegian EEA Financial Mechanism (HU0115/ NA/2008-3/DFI-9) and by Hungarian Research Grant KTIA-OTKA (CK-80745).
Ohio State University Biomedical Sciences endowed Professor.
The University of Kansas Cancer Center and the Kansas Bioscience Authority Stein Jacoby Fund while at FCCC. The author acknowledges support from
samples. AKG was funded by U01CA69631, 5U01CA113916, and the Eileen Weerasooriya and members of the Ontario Cancer Genetics Network for any of the collaborating centres in the BCFR, nor does mention of trade
necessarily reflect the views or policies of the National Cancer Institute or
(BCFR) and Principal Investigators. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. We wish to thank Teresa Selandler, Nayana Weerasooriya and members of the Ontario Cancer Genetics Network for their contributions to the study.
Beckman Research Institute of City of Hope (BRICOH)
The study was supported by the National Institutes of Health (RO1 CA74415 to SLN) and the Morris and Horowitz Families Endowment.
SWE-BRCA
SWE-BRCA collaborators: Per Karlsson, Margareta Nordling, Annika Bergman and Zakaria Einbeig, Gothenburg, Sahlgrenska University Hospital; Marie Stemmark-Axelmark and Sigrun Lidgren, Linköping University Hospital, Åke Borg, Niklas Nilsson, Ulrika Olsson, Maria Soller, Helena Iremoh, Katja Harbst and Karin Henriksson, Lund University Hospital, Annika Lindblom, Brita Arver, Anna von Wachenfeldt, Annelie Liljegren, Gisela Barbany-Bustindia and Johanna Rantala, Stockholm, Karolinska University Hospital; Beatrice Mellin, Henrik Gronberg, Eva-Lena Stattn and Monica Emmanuelsson, Umeå University Hospital; Hans Ehrenrönca, Richard Rosenquist and Niklas Dahll, Uppsala University Hospital.
U.K. and Gilda Radner Familial Ovarian Cancer Registry (URGFCOR)
UKFOCR was supported by a project grant from CRUK to Paul Pharoah. We thank Paul Pharoah, Susan Ramus, Carole Pye, Patricia Harrington and Eva Woźniak for their contributions towards the UKFOCR. We would like to acknowledge the Roswell Park Alliance Foundation for their continued support of the Gilda Radner Familial Cancer Family Registry. GRFOCR would like to acknowledge Kirsten Moysich and Lara Sucheston (Department of Cancer Prevention and Control).
University of Kansas Medical Center (KUMC)
We thank Ms. JoEllen Weaver for her help collecting patient data and samples. AKG was funded by U01CA69631, SU01CA113916, and the Eileen Stein Jacoby Fund while at FCCC. The author acknowledges support from
The University of Kansas Cancer Center and the Kansas Bioscience Agency, Eminent Scholar Program. AKG is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor.
University of Pennsylvania (UPENN)
This research was supported by the Breast Cancer Research Foundation (to KLN) and the Komen Foundation for the Cure (to SMD).
Women’s Cancer Program - Cedars-Sinai Medical Center (WCCR)
This work is supported by funding from the American Cancer Society Clinical Research Professorship (SIOP-06-258-COUL).
Author details
1Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK.
2Cancer Genomics Laboratory, Center Hospitalier Universitaire de Québec, 2705 Lauffer Boulevard, T3-57, Quebec City, QC Canada. Genetics and Population Health Division, Queensland Institute of Medical Research, 300 Herston Rd, Herston, Brisbane, QLD 4006, Australia. 3Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon/ Centre Léon Bérard, 28 rue Laennec, Lyon 69373, France and INSERM U1052, CNRS UMR5286, Université Lyon 1, Cancer Research Center of Lyon, 28 rue Laennec, Lyon 69373, France. 4Section of Genetic Oncology, Dept. of Laboratory Medicine, University and University Hospital of Pisa, Via Roma 57, 56125 Pisa, Italy.
5Department of Oncology, Lund University Hospital, Lund, Sweden.
6Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
7Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.
8Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala University, Uppsala, Sweden.
9Department of Oncology, Birmingham, UK.
10Sheffield Clinical Cancer Genetics Centre, General, Gothenburg, Sweden.
11Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
12Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
13Department of Genetics and Pathology, Pomeranian Medical University, Szczecin and Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.
14Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain and Spanish Network on Rare Diseases (CIBERER).
15Institute of Biology and Molecular Genetics, Universidad de Valladolid (IBGM-UVA), Valladolid, Spain.
16Oncology unit. Hospital clinic Universitario “Lozano Blesa”, Zaragoza, Spain.
17Human Genetics Group and Genotyping Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, Madrid, Spain and Spanish Network on Rare Diseases (CIBERER).
18Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.
19Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands.
20Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands.
21Department of Clinical Genetics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
22Department of Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands.
23Department of Clinical Genetics and GROM, School for Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands.
24Department of Clinical Genetics and GROM, School for Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands.
25Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
26Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands.
27Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
28Department of Medical Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
29Department of Medical Genetics, University Medical Center Utrecht, PO Box 85090, 3508 AB Utrecht, The Netherlands.
30Department of Clinical Genetics, University Medical Center Groningen, University Groningen, Groningen, The Netherlands.
31Netherlands Cancer Institute, Amsterdam, The Netherlands.
32Genetic Medicine, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
33Clinical Genetics, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK.
34Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK.
35Yorkshire Regional Genetics Service, Leeds, UK.
36Ferguson-Smith Centre for Clinical Genetics,Yorkhill Hospitals, Glasgow, UK.
37West Midlands Regional Genetics Service, Birmingham Women’s Hospital Healthcare NHS Trust, Edgbaston, Birmingham, UK.
38Sheffield Clinical Genetics Service, Sheffield Children’s Hospital, Sheffield, UK.
39Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
40Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter, UK.
41Medical Genetics Unit, St. George’s, University of London, UK.
42Northern Ireland Regional Genetics Centre, Belfast Health and Social Care Trust, and Department of Medical Genetics, Queens University Belfast, Belfast, UK.
43Oxford Regional Genetics Service, Churchill Hospital, Oxford, UK.
44All Wales Medical Genetics Services, University Hospital of Wales, Cardiff, UK.
45Clinical Genetics Department, St. Michael’s Hospital, Bristol, UK.
46North West Thames Regional Genetics Service, Kennedy-Galton Centre, Harrow,
Authors’ contributions
ACA, KBK and DFE wrote the manuscript. KBK performed the statistical analysis. ACA supervised the statistical analysis and data management. ACA, GCT and DFE developed the study design. LM and DB are the CIMBA database managers. AL wrote computer programs for the analysis. SH and OMS reviewed, re-coded and classified the BRCA1 and BRCA2 mutations in CIMBA. GCT initiated and coordinates CIMBA. PS, JB and YC performed the genotyping. AJ, SLN and GCT supervised the genotyping of samples. MAC, NL, KH, AL, BA, RR, PK, KN, SD, TR, AJ, JL, KJ, KD, EZ, AO, MD, RA, JB, UH, FBH, TAvO, SV, HEJHM, JW, EBGG, NlK, MlC, JMGEm, JCC0, SP, DF, SDE, RP, FP, DGE, FL, CJ, RE, JA, RD, TC, JC, JP, FD, CB, SH, PJM, LW, MTR, AD, HD, AKG, BB, DS, CH, BB, ADp, SM, AC, ML, BBdeP, OC, HS, MF, FP, SFF, IM, SB, MD, AM, MBT, JLM, EMl, MS, DG, CFG, AFR, MKT, DGT, GyCh, FCN, RBB, MK, TG, VJ, AD, KO, MP, JK, DC, HJ, JB, JF, AET, MM, CO, EI, C1, LT, IB, CL, AT, JDV, SAG, KO, JG, BKV, EO, SHT, PAg, CM, EDM, CnR, OD, AK, RKS, BW, CE, AM, ND, NA, SH, DN, SPA, DG, RVM, HD, AG, CS, KK, BF, DS, TC, Mdfil, HN, TAM, BL, ABS, SLN, YCD, XW, ZF, VSP, NML, PR, MmG, ITL, MLA, HO, AMM, GG, MT, AMG, UBI, ABS, TAK, GCT and FJC acquired phenotypic data and DNA samples or designed the centre-specific studies. All authors read and approved the final manuscript for publication.

Competing interests
The authors declare that they have no competing interests.

Received: 21 September 2011 Revised: 15 November 2011 Accepted: 20 February 2012 Published: 20 February 2012

References
1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Berg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Wanner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Petrovitz B, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2008, 82:1117-1130.

2. Begg CB, Haile R, Borg A, Malone KE, Conn cannon P, Thomas DC, Langholz B, Bernstein C, Olsen JH, Lynch CF. Average breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 mutation carriers. JAMA 2008, 299:194-201.

3. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, AMG, UBJ, ABS, TAK, GCT and FJC acquired phenotypic data and DNA samples or designed the centre-specific studies. All authors read and approved the final manuscript for publication.

4. Antoniou AC, Beesley J, McGuffog L, Carey LA, Aitken J, Antic J, Borski R, et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008, 82:937-948.

5. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley K, Simard J, Easton DF, Peock S, Allavena A, Dallolio O, Peterlongo P, Zaffaroni D, Ficarra F, et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Nat Genet 2011, 43:194-201.

6. Antoniou AC, Kartsonaki C, Spurdle AB, Healey S, Pooley KA, AMG, UBJ, ABS, TAK, GCT and FJC acquired phenotypic data and DNA samples or designed the centre-specific studies. All authors read and approved the final manuscript for publication.

7. Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Poock S, Cook M, Oliver F, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C, McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barhoux L, Frenay M, Michiel C, Leroux D, Dreyfus H, Toucas C, Gladieff L, Ulherrhomer N, Bignon YJ, Healey CS, Hughes M, Warren-Rutgers R, et al. Association of the variants CASP8 D302H and CASP10 V4140I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010, 19:2859-2868.

8. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredricksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roovers G, Barile M, et al. Allavena A, Ottini L, Papi L, Giommoni G, Capra F, Radice P, Greene MH, Alm P, Andrusz I, Glendon G, Ozcelik H, et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2010, 102:105-116.

9. Antoniou AC, Wang X, Fredricksen Z, McGuffog L, Marshall J, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Poock S, Cook M, Oliver F, Frost D, Eccles D, Evans DG, Rees L, Isatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasser C, Remenieras A, Caron O, et al. A focus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. J Med Genet 2010, 47:828-892.

10. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, Segre AV, McCabe K, McGuffog L, Kartsonaki C, Morrison J, Healey S, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Gauthier-Villars M, Sobol H, Longy M, Frenay M, Gemo SC, Hovestorf FB, Rookus MA, Colle JM, Hoogenbrugge N, van Roosendaal KE, Ped monte M, Rubinstein W, Nerenstein S, Van Le L, Blank SV, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010, 6:e1001183.

11. Cox DG, Simard J, Sinnott D, Hamdy F, Soucy P, Mair J, Bhatia L, Verrani-Piere C, McGuffog L, Healey S, Szabo C, Greene MH, Alm P, Andrusz I, Thomasen M, Genders AM, Caligo MA, Friedman E, Laitman Y, Kaufman B, Paluch SB, Gorg A, Kartlson P, Askmalm MS, Busitza GB, Nathanson K, Dornbeck SM, Rebeck TR, Benitez J, Hamme L, et al. Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. Hum Mol Genet 2011, 20:4732-4747.

12. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, van ‘t Veer LJ, de Groot R, Smt VT, Fasching PA, Bedweck MW, Jud S, Eski AB, Hartmann A, Heine Schulz-Wendtland R, Burwine V, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchohu S, Bojesen SE, Nordestgaard BG, Flyger H, Orsted DD, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumour subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011, 20:3289-3307.

13. Casado-Closs M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richeson DA, Bojesen SE, Nordestgaard BG, Axelson CK, Aris JL, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruning T, Haas S, Dock T, Schummann P, Hillelmann P, Bofigdanova N, Bremer M, Kantens JH, Fagerholm R, Aaltonen K, Attomaki K, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008, 4:e1000554.

14. Mulligan AG, Couch FJ, Bowarddale D, Dornbeck SM, Eccles D, Nevanlinna H, Ramus SJ, Robison M, Sherman M, Spurdle AB, Wapponschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavius C, Hansen TV, Nielsen FC, Ejlertsen B, Osorio A, Munoz-Repeto I, Duran M, Godino J, Petresi M, Benitez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, et al. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011, 13:R110.

15. Turnbull C, Ahmed S, Morrison J, Fernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, Hughes M, Warren-Rutgers K, Macgregor P, Hedges C, Lynch WS, Eccles D, Evans DG, Hooning M, Schutte M, van den Ouweland A, Houlston R, Ross G, Langford C, Pharoah PD, Stratton MR, Dunning AM, Rahman N, Easton DF. Genome-wide association study identifies five breast cancer susceptibility loci. Nat Genet 2010, 42:504-507.
16. Ghousaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, Dennis J, Wang Q, Humphreys MK, Luccarini C, Baynes C, Conroy D, Maranan M, Ahmed S, Driver K, Johnson N, Orr N, dos Santos Silva I, Walshez Q, Meijers-Heijboer H, Uttenweiler AG, Rivadeneira F, Nethertlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBOC), Hall P, Czene K, Iwamoto A, Liu J, Nevanlinna H, Attomaki K, Blomqvist C, Meindl A, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012.

17. Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, Zelenika D, Gut I, Heath S, Palles C, Coupland B, Broderick P, Schuurman M, Jones C, Williamson J, Chilcott-Burns S, Tomczyk Y, Simpson G, Jacobs KB, Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Antoniou AC, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, et al. Parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987, 237:893-896.

32. Asadi F, Kukreja S. Parathyroid hormone-related protein in prostate cancer. Crit Rev Eukaryot Gene Expr 2005, 15:15-28.

33. Linfort R, Anderson N, Hooey R, Nolan T, Downey S, Brady G, Ashcroft L, Bundred N. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin Cancer Res 2002, 8:3172-3177.

34. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, Brown J, Leyland J, Audley T, Wareham NJ, Loos RJ, Paterson AD, Rommers J, Waggott D, Martin LJ, Scott CG, Pankraz VS, Hankinson SE, Haza A, Hunter DJ, Hopper JL, Southey MC, Chanoek SJ, Silva IS, Liu J, Eriksson L, Couch FJ, Stone J, Apicella C, Czene K, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 2011, 43:185-187.

35. Mitchell G, Antoniou AC, Warren R, Peacock S, Brown J, Davies R, Mattison J, Cook M, Warsi I, Evans DG, Eccles D, Douglas F, Paterson J, Hodgson S, Izatt L, Cole T, Burgess L, Isles R, Easton DF. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 2006, 66:1866-1872.

36. Bolton KL, Tyer J, Song H, Ramus SJ, Notarioudi M, Jones C, Sher T, Gentry-Maharaj A, Vozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziegas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Seh W, McGuire V, Whitemore AS, Campbell I, Gore ME, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2011, 43:880-884.

37. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notarioudi M, Lawson K, Widschwendter M, Verkaart RA, Larson MC, Kyer SK, Birrer MJ, Berchuck A, Schröder J, Tomlinson I, Kemeny LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whitemore AS, Sutphen R, Phelan C, Anton-Culver H, Pierce CL, Lambrechtts D, Rossing MA, Chang-Claude J, Moyisch KB, Goodman MT, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010, 42:874-879.

38. Song H, Ramus SJ, Tyer J, Bolton KL, Gentry-Maharaj A, Vozniak E, Anton-Culver H, Chang-Claude J, Crummer DW, Dicicco-Ri J, Dorst K, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dickes E, Doherty JA, Dust M, Eeckhout F, Fenstermacher D, Friel RL, Giles G, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009, 41:996-1000.

39. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011, 22(Suppl 1):i11-i17.

Cite this article as: Antoniou et al.: Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Research 2012 14:R33.